Cisplatin is a potent anticancer drug for treating tumors, that has long been widely used. The therapeutic exploitation of cisplatin is limited by its toxicity toward healthy tissues. Liposomes can provide enhanced efficacy and/or reduced toxicity and these systems offer the potential to enhance the therapeutic index of anticancer agents. In this study, cisplatin liposomes were developed and characterized in vitro. The cytotoxicity test was used to determine Caco-2 cell viability and the IC50 values of free cisplatin was found 20 μg/mL. Release and transport studies of cisplatin through dialyse membrane and Caco-2 cells were investigated. The stability of liposomes was developed when stored at three different temperature for 3 months. The mean particle size and average zeta-potential of the cisplatin liposomes were approximately 285±0.052 nm and 2.45±0.65 mV, respectively. Cisplatin release from dialyse membrane and transport through Caco-2 cells were obtained as 53.9±2.71 % and 46.2±1.61 % respectively. Significant particle size increase and zeta potantial decrease were not observed in cisplatin liposomes after 3 months when stored at 4ºC (p>0.01). Consequently cisplatin liposomes can be delivered orally and repre-sent a potential therapeutic modality in the treatment of tumors.

Keywords: Liposome, Cisplatin, Caco-2 cell line, Cytotoxicity